*Sponsored
Krypton Street Announces Coverage On Enveric Biosciences (NASDAQ: ENVB) Starting This Morning—Thursday, August 28, 2025
Here's Why (ENVB) Just Hit Our Watchlist This Morning:
Analyst Target: HC Wainwright's Vernon Bernardino Set A $10 Target On (ENVB), Which Suggests 600% Upside Potential From Its Recent Range.
Razor-Thin Float: (ENVB) Has Fewer Than 3.3M Shares Listed In Its Float, Which Could Create The Potential For Sharp Moves If Demand Starts To Shift.
Recent Momentum: (ENVB) Just Made An Approximate 37% Move In Two Weeks, From $1.05 On August 13 To $1.44 Yesterday.
Pull Up (ENVB) Before 3PM EST…
August 28, 2025
Fast Scan | Could (ENVB) Be Flirting With a Red to Green Flip? Take A Look Now Dear Reader, As we are trending into the afternoon session, we have our eyes on (ENVB) as technicals are flirting with a potential Red-to-Green flip. The (ENVB) team finished 7-day pre-IND dose-finding for EB-003 in two species, set the MTD, and verified oral exposure with CNS signals that point to brain activity. Translation: the lane is clear to push IND-enabling studies and tighten plans for First-in-Human. See full story here. Let's be honest: waiting weeks for antidepressants to kick in—if they ever do—doesn't cut it. Too many people never see relief. This morning, a different kind of player crossed our screen: Enveric Biosciences (NASDAQ: ENVB), pushing for faster, longer-lasting effects without the baggage that holds legacy approaches back. If you're reading this, you're early. Here's why we're dialed in right now:
Limited Float: With a small float of less than 3.3M shares listed as available for the public—(ENVB) has the potential to witness big moves if there's a change in demand. Recent Momentum: (ENVB) just made an approximate 37% move, from $1.05 on Aug 13 to $1.44 yesterday. Trend Check: (ENVB) is now trending above its 5, 20, 50, and 100-Day moving averages, with a long runway ahead to the 200-Day, at around $2.49. Coverage On Record: HC Wainwright's Vernon Bernardino set a $10 target on (ENVB) earlier this year—which suggests 600% upside potential from its recent $1.30 range. 
With potential momentum building on the chart, its trending technicals, and analyst coverage, the real story lies beneath the surface—what this company is actually developing. Because behind the scenes is a bold plan to change the way mental health is treated—one that could set (ENVB) apart from nearly everything else in the space right now. Next-Gen Brain Reset, Not Yesterday's Playbook
Enveric Biosciences (NASDAQ: ENVB) is working to change how difficult psychiatric conditions are treated. Instead of leaning on decades-old solutions, the company is developing next-generation compounds built to help the brain rewire itself—while avoiding the hallucinatory side effects that limit psychedelic-based therapies. 
Leading the pipeline is EB-003, a non-hallucinogenic, orally available candidate. Unlike current treatments that can take weeks to show effect—or trial-stage therapies that require hours of in-clinic supervision—EB-003 has been designed for convenience and speed, aiming to deliver fast, durable relief in a way that could fit into everyday life. Statistically Significant: EB-003 Improved Measures In Depression Models
Early signs are compelling. In a validated PTSD model, a single oral dose of EB-003 reduced fear-conditioned responses. In depression testing, EB-003 produced statistically significant improvements on standard behavior measures. Importantly, the current profile supports the idea that EB-003 can be given daily, which sets it apart from hallucinatory approaches that require infrequent, supervised sessions. Taken together, these results point to a path that could be both effective and practical in real-world care. Upgrade The Wiring, Level The Mood
Think of EB-003 as aiming to do two things at once: help the brain form healthier connections and keep mood and motivation on a steadier track. That combination targets deeper circuit-level balance rather than just smoothing over surface symptoms, which is why the approach could feel different from what's out there today. From Discovery To Pipeline: How Psybrary™ Feeds What's Next
(ENVB) isn't a one-program story. Its Psybrary™ platform is a proprietary engine for designing and refining new small molecules for psychiatric and neurological conditions. From that engine, the EVM-301 series explores novel tryptamine-based chemistry, while the EVM-401 series—recently strengthened by a second U.S. patent allowance—focuses on non-hallucinogenic mescaline-inspired derivatives with potential across PTSD, ADHD, and substance-related conditions. The company has also licensed earlier assets, creating more than one path to value from the pipeline. (ENVB)'s Recent Media Coverage
- Pharmaceutical Online: Spotlighted a non-hallucinogenic, clinic-friendly path built for scale.
- Microdose: Labeled the company "poised to outshine traditional targets."
- Life Science Leader: Framed the "no-trip" approach as aligned with next-gen psychiatry.
- Labiotech: Included (ENVB) among six notable mental-health innovators.
Bottom line: (ENVB) is shifting from niche to noticed, with coverage zeroing in on its practical, non-hallucinogenic strategy. Demand Meets Direction
The gap in care is massive: roughly 65M people in the U.S. will face a serious psychiatric disorder over their lifetime, and nearly half don't respond to first-line antidepressants that can take 4–6 weeks to even start working. Enveric is building toward a faster, more practical approach that aims to fit real life for patients and clinicians. Analysts peg the global market for neuroplastogen-based treatments at $35B+ by 2030, and Enveric is moving early with a differentiated pipeline to meet that momentum. As of June 30, 2025, the company reported $2.8M in cash and $4.9M raised in net proceeds during the first half of the year to support progress. Near term, the focus is clear: complete the remaining IND-enabling work for EB-003 and submit a U.S. IND in early 2026—the gateway to first-in-human study. 
Here's 7 Reasons Why (ENVB) Just Landed On Our Radar This Morning
—Thursday, August 28, 2025
1. Analyst Coverage: earlier this year, HC Wainwright's Vernon Bernardino issued a $10 target on (ENVB), which suggests more than 600% upside potential from its recent range.
2. Razor-Thin Float: with fewer than 3.3M shares listed in its float, (ENVB) has the potential to witness sharp moves if demand begins to shift. 3. Recent Momentum: in just the past two weeks, (ENVB) made an approximate 37% move, from $1.05 on August 13 to $1.44 yesterday. 4. Technical Signals: (ENVB) is now trending above its 5, 20, 50, and 100-Day Moving Averages, showing strength across multiple timeframes. 5. Pipeline Strength: (ENVB) is advancing EB-003, a next-generation candidate designed to deliver faster, durable relief without the hallucinatory roadblocks of classic ps-ych-ede-lics. 6. Near-Term Milestone: (ENVB) is preparing to file its IND for EB-003 in early 2026, a key step toward its first-in-human clinical trial. 7. Growing Attention: (ENVB) has recently been featured in Pharmaceutical Online, Micro-dose, Life Science Leader, and Labiotech for its "no-trip" neuroplastogen strategy. Pull Up (ENVB) Before 3PM EST…
Company's Website & Corporate Presentation With an ultra-small float, approximate 37% recent move, and technical strength across key technical levels, (ENVB) is already showing signs of building traction. Add in analyst coverage pointing to a $10 target, a pipeline led by EB-003 designed to avoid the roadblocks that slowed traditional approaches, and media attention from top industry outlets, and you can see why this company is starting to separate itself from the pack. Looking ahead, the early 2026 IND filing marks a clear milestone that could put (ENVB) directly in the spotlight. This just landed on our radar, and the setup is hard to ignore. We have all eyes on (ENVB) this morning. Take a look at this while it's still early. Also—my next update could be hitting any moment, make sure you're watching out for it. Sincerely, Alex Ramsay
Co-Founder / Managing Editor Krypton Street Newsletter | 
